Today: 19 March 2026
Subscribe
Browse Category

Stock Market 17 January 2026

Home Depot stock price in focus as investors seek answers on surveillance data ahead of Fed meeting

Home Depot stock price in focus as investors seek answers on surveillance data ahead of Fed meeting

Home Depot closed at $380.17, up 0.27%, as shareholders pressed the company to assess privacy and civil rights risks tied to license-plate reader cameras linked to immigration enforcement. Zevin Asset Management and 17 co-filers submitted a proposal demanding scrutiny of surveillance data practices. A spokesperson said Home Depot cannot legally interfere with federal agencies. Rival Lowe’s ended at $277.55, up 0.2%.
17 January 2026
··
Agricultural Bank of China A-shares slide again — 601288 investors eye Monday’s margin-rule reset

Agricultural Bank of China A-shares slide again — 601288 investors eye Monday’s margin-rule reset

Agricultural Bank of China’s Shanghai A shares fell 1.6% to 7.21 yuan Friday, capping a 5% slide over three sessions as trading volume reached 372 million shares. Mainland exchanges will raise margin requirements to 100% on Monday, while the central bank cuts rates on targeted lending tools. Other major banks and the CSI 300 index also declined. Outstanding yuan loans hit 271.91 trillion yuan at year-end, up 6.4% from 2024.
17 January 2026
··
Bank of America stock price: BAC heads into a long weekend with rates and earnings still driving trade

Bank of America stock price: BAC heads into a long weekend with rates and earnings still driving trade

Bank of America shares rose 0.7% to $52.97 Friday, with about 52 million shares traded. The bank reported Q4 net income of $7.6 billion on $28.4 billion in revenue and reaffirmed its 2026 net interest income growth forecast. The NYSE will pause Monday for Martin Luther King Jr. Day. The 10-year Treasury yield closed at 4.24%.
17 January 2026
···
Netflix stock price holds near $88 as Sony film deal and Warner bid set up Tuesday earnings

Netflix stock price holds near $88 as Sony film deal and Warner bid set up Tuesday earnings

Netflix closed at $88.00 Friday, slipping 0.06%, then rose 0.5% after hours ahead of its Q4 results Tuesday. The company’s $82.7 billion bid for Warner Bros Discovery faces competition from Paramount Skydance and awaits regulatory approval. Analysts expect $11.97 billion in quarterly revenue and about 10 million new subscribers. Director Bradford L. Smith sold shares at $88–$90 this week, retaining nearly 80,000.
17 January 2026
·····
Alibaba stock price slips 3% into weekend as Qwen AI rollout meets China data week

Alibaba stock price slips 3% into weekend as Qwen AI rollout meets China data week

Alibaba shares fell 3.2% to $165.40 Friday, ending a short rally before the U.S. market holiday. The company upgraded its Qwen AI app this week, adding food delivery and travel booking features now in public testing across China. China’s GDP and activity data will be released Monday, with markets watching for signs of slowing growth.
17 January 2026
···
Costco stock price closes near $964 as COST dividend dates and Fed meeting come into focus

Costco stock price closes near $964 as COST dividend dates and Fed meeting come into focus

Costco shares closed Friday up 0.7% at $963.61 after the company declared a $1.30 quarterly dividend, payable Feb. 13 to shareholders on record Jan. 30. U.S. stock markets will close Monday for Martin Luther King Jr. Day and reopen Tuesday. The S&P 500 slipped 0.06% Friday, while the Dow fell 0.17%. Fed officials signaled no imminent policy shift ahead of the Jan. 27-28 meeting.
17 January 2026
··
1 … 455 456 457 458 459 … 1,355

Stock Market Today

  • Soligenix Publishes HyBryte Clinical Data Validating Safety and Efficacy
    March 19, 2026, 2:04 PM EDT. Soligenix (NASDAQ: SNGX), a biopharmaceutical firm targeting rare diseases, reported the publication of clinical trial data on HyBryte (synthetic hypericin) in the peer-reviewed journal Expert Opinion on Investigational Drugs. The summary underscores HyBryte's safety profile, non-mutagenic mechanism, and demonstrated efficacy against cutaneous T-cell lymphoma (CTCL). The data supports HyBryte's potential as a first-line treatment. Soligenix continues its ongoing FLASH2 Phase 3 trial for HyBryte, with an interim analysis slated for Q2 2026. The company focuses on rare disease therapies and vaccine programs underpinned by proprietary technology. This publication bolsters investor confidence as Soligenix advances regulatory efforts toward global commercialization of HyBryte, expanding its pipeline across inflammatory and infectious diseases.
Go toTop